Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B

N. Gara, X. Zhao, M. T. Collins, W. H. Chong, D. E. Kleiner, T. Jake Liang, M. G. Ghany, J. H. Hoofnagle

Research output: Contribution to journalArticle

Abstract

Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (

Original languageEnglish (US)
Pages (from-to)1317-1325
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume35
Issue number11
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Tenofovir
Chronic Hepatitis B
Kidney
Nucleotides
Fanconi Syndrome
National Institutes of Health (U.S.)
Proteinuria
Creatinine
Therapeutics
Phosphates
Incidence
Serum
adefovir

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Gara, N., Zhao, X., Collins, M. T., Chong, W. H., Kleiner, D. E., Jake Liang, T., ... Hoofnagle, J. H. (2012). Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 35(11), 1317-1325. https://doi.org/10.1111/j.1365-2036.2012.05093.x

Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. / Gara, N.; Zhao, X.; Collins, M. T.; Chong, W. H.; Kleiner, D. E.; Jake Liang, T.; Ghany, M. G.; Hoofnagle, J. H.

In: Alimentary Pharmacology and Therapeutics, Vol. 35, No. 11, 06.2012, p. 1317-1325.

Research output: Contribution to journalArticle

Gara, N, Zhao, X, Collins, MT, Chong, WH, Kleiner, DE, Jake Liang, T, Ghany, MG & Hoofnagle, JH 2012, 'Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B', Alimentary Pharmacology and Therapeutics, vol. 35, no. 11, pp. 1317-1325. https://doi.org/10.1111/j.1365-2036.2012.05093.x
Gara, N. ; Zhao, X. ; Collins, M. T. ; Chong, W. H. ; Kleiner, D. E. ; Jake Liang, T. ; Ghany, M. G. ; Hoofnagle, J. H. / Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. In: Alimentary Pharmacology and Therapeutics. 2012 ; Vol. 35, No. 11. pp. 1317-1325.
@article{376bc65456a34c85a335df90b788afed,
title = "Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B",
abstract = "Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14{\%}) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15{\%}. All seven had low urinary percent maximal tubular reabsorption of phosphate (",
author = "N. Gara and X. Zhao and Collins, {M. T.} and Chong, {W. H.} and Kleiner, {D. E.} and {Jake Liang}, T. and Ghany, {M. G.} and Hoofnagle, {J. H.}",
year = "2012",
month = "6",
doi = "10.1111/j.1365-2036.2012.05093.x",
language = "English (US)",
volume = "35",
pages = "1317--1325",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B

AU - Gara, N.

AU - Zhao, X.

AU - Collins, M. T.

AU - Chong, W. H.

AU - Kleiner, D. E.

AU - Jake Liang, T.

AU - Ghany, M. G.

AU - Hoofnagle, J. H.

PY - 2012/6

Y1 - 2012/6

N2 - Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (

AB - Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (

UR - http://www.scopus.com/inward/record.url?scp=84860519158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860519158&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2012.05093.x

DO - 10.1111/j.1365-2036.2012.05093.x

M3 - Article

C2 - 22506503

AN - SCOPUS:84860519158

VL - 35

SP - 1317

EP - 1325

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 11

ER -